Gregory Robert Mundy DeceasedSan Antonio, TX

6342514, Jan 29, 2002

Feb 28, 1997

08/808741

Charles Petrie - Woodinville WA
Mark W. Orme - Seattle WA
Nand Baindur - Edmonds WA
Kirk G. Robbins - Renton WA
Maria Kontoyianni - Seattle WA
Gregory R. Mundy - San Antonio TX

ZymoGenetics, Inc. - Seattle WA
Osteoscreen, Inc. - San Antonio TX

A61K 31495

514367, 514311, 514312, 514313, 514314, 514432, 514451, 514452, 514360

Compounds containing two aromatic systems covalently linked through a linker containing one or more atoms, or âlinkerâ defined as including a covalent bond per se so as to space the aromatic systems at a distance 1. 5-15 , are effective in treating conditions associated with bone deficits. The compounds can be administered to vertebrate subjects alone or in combination with additional agents that promote bone growth or that inhibit bone resorption. They can be screened for activity prior to administration by assessing their ability to effect the transcription of a reporter gene coupled to a promoter associated with a bone morphogenetic protein and/or their ability to stimulate calvarial growth in model animal systems.

6376476, Apr 23, 2002

Jan 20, 2000

09/488380

Shirley R. Gasper - Seattle WA
Robert R. West - Seattle WA
Theresa Martinez - Greenbank WA
Kirk G. Robbins - Renton WA
Patricia A. McKernan - Woodinville WA
Nand Baindur - Edmonds WA
Virender M. Labroo - Bangalore, IN
Gregory R. Mundy - San Antonio TX

ZymoGenetics Corporation - Seattle WA
OsteoScreen, Inc. - San Antonio TX

A61K 31665

514100, 514333, 514374

Various embodiments of statin compounds are shown to enhance the formation of bone and are thus useful in treating osteoporosis, bone fracture or deficiency, primary or secondary hyperparathyroidism, periodontal disease or defect, metastatic bone disease, osteolytic bone disease, post-plastic surgery, post-prosthetic joint surgery, and post-dental implantation.

6410512, Jun 25, 2002

Jul 27, 1999

09/361775

Gregory R. Mundy - San Antonio TX
I. Ross Garrett - San Antonio TX
G. Rossini - San Antonio TX

OsteoScreen, Inc. - San Antonio TX

A61K 3800

514 12, 514880

Compounds that inhibit the activity of NF- B or inhibit the activity of the proteasome or both promote hair growth and stimulate the production of hair follicles and are thus useful in stimulating hair growth, including hair density, in subject where this is desirable.

6410521, Jun 25, 2002

Apr 3, 2000

09/541943

Gregory R. Mundy - San Antonio TX
I. Ross Garrett - San Antonio TX
Gloria E. Gutierrez - San Antonio TX

OsteoScreen, Inc. - San Antonio TX

A01N 5700

514100, 514451

A food or food supplement which comprises a compound that enhances bone growth in vertebrates is described wherein the food or foodstuff is formulated so as to provide the desired bone growth enhancing effect.

6413998, Jul 2, 2002

Dec 2, 1999

09/453828

Charles Petrie - Woodinville WA
Mark V. Craig - Seattle WA
Nand Baindur - Edmonds WA
Kirk G. Robbins - Renton WA
Scott M. Harris - Seattle WA
Maria Kontoyianni - Seattle WA
Gregory R. Mundy - San Antonio TX

Osteoscreen, Inc. - San Antonio TX

A61K 3112

514367, 514434, 514453, 514456, 514533, 514617, 514685

Compounds containing two aromatic systems covalently linked through a linker containing one or more atoms, or âlinkerâ defined as including a covalent bond per se so as to space the aromatic systems at a distance 1. 5-15 , are effective in treating conditions associated with bone deficits. The compounds can be administered to vertebrate subjects alone or in combination with additional agents that promote bone growth or that inhibit bone resorption. They can be screened for activity prior to administration by assessing their ability to effect the transcription of a reporter gene coupled to a promoter associated with a bone morphogenetic protein and/or their ability to stimulate calvarial growth in model animal systems.

6462019, Oct 8, 2002

Jul 10, 1998

09/113947

Gregory R. Mundy - San Antonio TX
I. Ross Garrett - San Antonio TX
G. Rossini - San Antonio TX

OsteoScreen, Inc. - San Antonio TX

A61K 3800

514 12, 435 692

Compounds that inhibit the activity of NF- B or inhibit the activity of the proteasome or both promote bone formation and are thus useful in treating osteoporosis, bone fracture or deficiency, primary or secondary hyperparathyroidism, periodontal disease or defect, metastatic bone disease, osteolytic bone disease, post-plastic surgery, post-prosthetic joint surgery, and post-dental implantation.

6492333, Dec 10, 2002

Apr 9, 1999

09/289229

Gregory R. Mundy - San Antonio TX

Osteoscreen, Inc. - San Antonio TX

A61K 3800

514 18, 514 12, 514 13, 514613, 514617

The present invention involves the identification and use of compositions for treating myeloma bone disease. The compositions inhibit proteasomal activity and decrease the activity of the transcription factor NF- B. Assessment of a candidate compound for its ability to inhibit production or activity of proteasomal enzymes or NF- B provides a useful means to identify agents to treat myeloma bone disease.

6649631, Nov 18, 2003

Nov 19, 1999

09/297188

Mark W. Orme - Seattle WA
Nand Baindur - Edmonds WA
Kirk G. Robbins - Rendon WA
Scott M. Harris - Seattle WA
Maria Kontoyianni - Seattle WA
Laurence H. Hurley - Austin TX
Sean M. Kerwin - Round Rock TX
Gregory Mundy - San Antonio TX
Charles Petrie - Woodinville WA

The Board of Regents of the University of Texas System - Austin TX
ZymoGenetics Corporation - Seattle WA
OsteoScreen - San Antonio TX

A61K 3144

514332, 514334, 514255, 514275, 514256, 514242, 514245

Compounds containing two aromatic systems covalently linked through a linker containing one or more atoms, or âlinkerâ defined as including a covalent bond per se so as to space the aromatic systems at a distance 1. 5-15 , are effective in treating conditions associated with bone deficits. The compounds can be administered to vertebrate subjects alone or in combination with additional agents that promote bone growth or that inhibit bone resorption. They can be screened for activity prior to administration by assessing their ability to effect the transcription of a reporter gene coupled to a promoter associated with a bone morphogenetic protein and/or their ability to stimulate calvarial growth in model animal systems.